← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV25행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinicalPreclinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
Midostaurin (Midostaurin)
Syndax Pharmaceuticals·Acute Myeloid Leukemia
31 trials
Overview
Program
Midostaurin
Overview
Company
Syndax Pharmaceuticals
Overview
Modality
CGT
Overview
Target
Acute Myeloid Leukemia
Overview
Indication
Acute Myeloid Leukemia; AML, Adult
Overview
Phase
PHASE_1
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
MoA
Mechanism
targeting of mutant p53 with eprenetapopt or MAPK signaling
MoA
Biomarker
biomarker with prognostic significance and immunotherapeutic implications, particularly in prostate cancer
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse
Toxicology
Major finding
thrombocytopenia
Clinical
Safety signal
thrombocytopenia
Clinical
Reported OS
20
Clinical
Result source
ClinicalTrials.gov NCT00233454
Clinical
Program phase
PHASE_1
Clinical
Trial ref
NCT00233454
Preclinical
Animal (cat.)
Mouse